Literature DB >> 32389221

Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.

Deborah A Marshall1, Luiza R Grazziotin2, Dean A Regier3, Sarah Wordsworth4, James Buchanan4, Kathryn Phillips5, Maarten Ijzerman6.   

Abstract

OBJECTIVES: The objective of this article is to describe the unique challenges and present potential solutions and approaches for economic evaluations of precision medicine (PM) interventions using simulation modeling methods.
METHODS: Given the large and growing number of PM interventions and applications, methods are needed for economic evaluation of PM that can handle the complexity of cascading decisions and patient-specific heterogeneity reflected in the myriad testing and treatment pathways. Traditional approaches (eg, Markov models) have limitations, and other modeling techniques may be required to overcome these challenges. Dynamic simulation models, such as discrete event simulation and agent-based models, are used to design and develop mathematical representations of complex systems and intervention scenarios to evaluate the consequence of interventions over time from a systems perspective.
RESULTS: Some of the methodological challenges of modeling PM can be addressed using dynamic simulation models. For example, issues regarding companion diagnostics, combining and sequencing of tests, and diagnostic performance of tests can be addressed by capturing patient-specific pathways in the context of care delivery. Issues regarding patient heterogeneity can be addressed by using patient-level simulation models.
CONCLUSION: The economic evaluation of PM interventions poses unique methodological challenges that might require new solutions. Simulation models are well suited for economic evaluation in PM because they enable patient-level analyses and can capture the dynamics of interventions in complex systems specific to the context of healthcare service delivery.
Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  economic evaluation; precision medicine; simulation model

Mesh:

Year:  2020        PMID: 32389221      PMCID: PMC7218800          DOI: 10.1016/j.jval.2020.01.016

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  38 in total

Review 1.  Precision Medicine: From Science To Value.

Authors:  Geoffrey S Ginsburg; Kathryn A Phillips
Journal:  Health Aff (Millwood)       Date:  2018-05       Impact factor: 6.301

Review 2.  Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.

Authors:  Deborah A Marshall; Lina Burgos-Liz; Maarten J IJzerman; William Crown; William V Padula; Peter K Wong; Kalyan S Pasupathy; Mitchell K Higashi; Nathaniel D Osgood
Journal:  Value Health       Date:  2015-03       Impact factor: 5.725

3.  Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4.

Authors:  Jonathan Karnon; James Stahl; Alan Brennan; J Jaime Caro; Javier Mar; Jörgen Möller
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

Review 4.  Recent developments in decision-analytic modelling for economic evaluation.

Authors:  Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Health Care System Information Sharing: A Step Toward Better Health Globally.

Authors:  Randa Eldessouki; Marilyn Dix Smith
Journal:  Value Health Reg Issues       Date:  2012-05-25

6.  Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force.

Authors:  William Crown; Nasuh Buyukkaramikli; Praveen Thokala; Alec Morton; Mustafa Y Sir; Deborah A Marshall; Jon Tosh; William V Padula; Maarten J Ijzerman; Peter K Wong; Kalyan S Pasupathy
Journal:  Value Health       Date:  2017-03       Impact factor: 5.725

7.  Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Authors:  Ahmad Tarhini; Agnes Benedict; David McDermott; Sumati Rao; Apoorva Ambavane; Komal Gupte-Singh; Javier Sabater; Corey Ritchings; Valerie Aponte-Ribero; Meredith M Regan; Michael Atkins
Journal:  Immunotherapy       Date:  2018-09-03       Impact factor: 4.196

8.  Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

Authors:  O Trédan; Q Wang; D Pissaloux; P Cassier; A de la Fouchardière; J Fayette; F Desseigne; I Ray-Coquard; C de la Fouchardière; D Frappaz; P-E Heudel; A Bonneville-Levard; A Fléchon; M Sarabi; P Guibert; T Bachelot; M Pérol; B You; N Bonnin; O Collard; C Leyronnas; V Attignon; C Baudet; E Sohier; J-P Villemin; A Viari; S Boyault; S Lantuejoul; S Paindavoine; I Treillleux; C Rodriguez; V Agrapart; V Corset; G Garin; S Chabaud; D Pérol; J-Y Blay
Journal:  Ann Oncol       Date:  2019-05-01       Impact factor: 32.976

Review 9.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

10.  Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models.

Authors:  Koen Degeling; Maarten J IJzerman; Miriam Koopman; Hendrik Koffijberg
Journal:  BMC Med Res Methodol       Date:  2017-12-15       Impact factor: 4.615

View more
  7 in total

1.  Cost-Effectiveness of Pre-exposure Prophylaxis Among Men Who Have Sex With Men in China: A Systematic Review.

Authors:  Yuanqi Mi; Yuhong Zeng; Peicheng Wang; Mengge Zhou; Feng Cheng
Journal:  Front Public Health       Date:  2022-06-21

2.  Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.

Authors:  Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; László Szilberhorn; Tamás Zelei; Balázs Nagy; Rositsa Koleva-Kolarova; Apostolos Tsiachristas; Sarah Wordsworth; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2021-04-16       Impact factor: 4.981

3.  Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer.

Authors:  Michiel van de Ven; Maarten IJzerman; Valesca Retèl; Wim van Harten; Hendrik Koffijberg
Journal:  BMC Med Res Methodol       Date:  2022-03-27       Impact factor: 4.615

4.  Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.

Authors:  Martin Vu; Koen Degeling; Ella R Thompson; Piers Blombery; David Westerman; Maarten J IJzerman
Journal:  Eur J Haematol       Date:  2022-03-02       Impact factor: 3.674

Review 5.  Cost-Effectiveness Analysis of COVID-19 Vaccination in Low- and Middle-Income Countries.

Authors:  Auliasari M Utami; Farida Rendrayani; Qisty A Khoiry; Fitri Alfiani; Arif S W Kusuma; Auliya A Suwantika
Journal:  J Multidiscip Healthc       Date:  2022-09-13

6.  Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation.

Authors:  Robin Z Hayeems; Francois Bernier; Kym M Boycott; Taila Hartley; Christine Michaels-Igbokwe; Deborah A Marshall
Journal:  BMJ Open       Date:  2022-10-10       Impact factor: 3.006

Review 7.  Cost-effectiveness of precision diagnostic testing for precision medicine approaches against non-small-cell lung cancer: A systematic review.

Authors:  Raymond Henderson; Peter Keeling; Declan French; Dave Smart; Richard Sullivan; Mark Lawler
Journal:  Mol Oncol       Date:  2021-07-19       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.